Biotech has rceived a notice of allowance from the USPTO for a patent application covering the company's long-acting CTP-enhanced human growth hormone (hGH-CTP).
Once the patent is issued, PROLOR would gain additional intellectual property protection covering methods for the induction of growth in growth hormone deficient patients.
PROLOR president Shai Novik said, "We have several other CTP-related patent applications that are currently pending, and we believe that this growing patent portfolio will reinforce our existing patent estate for our CTP-enhanced compounds in development, as well as for our CTP platform technology generally."
The company's Phase II trial of hGH-CTP in growth hormone deficient adults demonstrated that a single weekly injection has the potential to reduce the required dosing frequency of human growth hormone from the current standard of one injection per day to a single weekly injection.
